FDA Rejects Epix' Vasovist Appeal
Posted on: Wednesday, 30 August 2006, 12:00 CDT
The FDA has rejected Epix Pharmaceutical's appeal to approve its novel blood pool imaging agent Vasovist. A request for an advisory committee to review Vasovist was also turned down.
Epix submitted the appeal to the FDA's Office of New Drugs (OND) on June 30, 2006 in response to two prior approvable letters for Vasovist. Epix were also told by the FDA that conducting two new clinical trials would be needed if they were going to secure a third approval and would be safer than using data from a previous clinical trial.
"We are evaluating several options available to us as next steps with Vasovist in the US, including the option to appeal this decision to the next level at the FDA, and will update the market accordingly," said Andrew Uprichard President of Epix Pharmaceuticals.
Vasovist was approved in the European Union and Switzerland last year. Vasovist has also been recommended for approval in Australia.
Source: Datamonitor
Related Articles
- EPIX Pharmaceuticals Announces First Quarter Financial Results
- EPIX Pharmaceuticals to File Appeal With the Center for Drug Evaluation and Research for Vasovist(TM)
- EPIX Pharmaceuticals Receives Response From the FDA Regarding Appeal of Vasovist(TM) Approvable Letters
- EPIX and Predix Pharmaceuticals Complete Merger
- EPIX Reports Second Quarter 2006 Results
- EPIX Pharmaceuticals Retains Full Rights to Fibrin-Binding Imaging Agent EP-2104R As Schering AG Decides Not to Exercise Option for Development Program; Company To Seek Development and Marketing Partner for EP-2104R
- FDA Has No Designs on Supplement Laws
- FDA's Utah Medical Lawsuit is Dismissed
- FDA Accepts EPIX' Submission Following Vasovist(TM) Approvable Letter As Complete Response
 |
 |
User Comments (0)
RSS Feeds